SCHEMBL16634078

SCHEMBL16634078

CC(C)(C)N(C(=O)O)C(CN)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MMP2 P08253 2/20 0.38
MMP9 P14780 2/20 0.38
SERPINE1 P05121 1/20 0.38
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
SPPL2B Q8TCT7 1/20 0.37
SPPL2A Q8TCT8 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
SLC7A5 Q01650 2/20 0.37
EPHX2 P34913 2/20 0.37
SLC6A2 P23975 3/20 0.37
SLC6A4 P31645 3/20 0.37
NR1H4 Q96RI1 1/20 0.36
GRIK1 P39086 1/20 0.36
GRIK2 Q13002 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16633980 0.88 ALDH1A1 (0.41) EPHX1ALDH1A1MMP2MMP9SERPINE1
SCHEMBL16632995 0.87 EPHX1 (0.41) EPHX1ALDH1A1MMP2MMP9SERPINE1
SCHEMBL16633204 0.86 MMP2 (0.40) EPHX1ALDH1A1MMP2MMP9SERPINE1
SCHEMBL16633428 0.84 ALDH1A1 (0.38) EPHX1ALDH1A1MMP2MMP9SERPINE1
SCHEMBL16633172 0.84 ALDH1A1 (0.38) EPHX1ALDH1A1MMP2MMP9SERPINE1
SCHEMBL16633307 0.84 ALDH1A1 (0.38) EPHX1ALDH1A1MMP2MMP9SERPINE1
SCHEMBL16633119 0.81 SLC6A4 (0.47) EPHX2SLC6A2SLC6A4
SCHEMBL16633233 0.80 EPHX1 (0.43) EPHX1ALDH1A1SERPINE1PSEN1PSEN2
SCHEMBL1231239 0.80 SLC6A2 (0.42) SLC6A2SLC6A4
SCHEMBL14909537 0.80 SLC6A2 (0.42) SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469637-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-18 US disclosed
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A EPHX1 1515/4885ALDH1A1 492/4885MMP2 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.